Previous Article | Next Article 
Molecular and Cellular Biology, October 1999, p. 6690-6698, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Roles of Cell Division and Gene Transcription
in the Methylation of CpG Islands
Christina M.
Bender,
Mark L.
Gonzalgo,
Felicidad A.
Gonzales,
Carvell T.
Nguyen,
Keith D.
Robertson, and
Peter A.
Jones*
Urologic Research Laboratory, USC/Norris
Comprehensive Cancer Center, University of Southern California
School of Medicine, Los Angeles, California 90089-9181
Received 4 March 1999/Returned for modification 13 April
1999/Accepted 7 July 1999
 |
ABSTRACT |
De novo methylation of CpG islands within the promoters of
eukaryotic genes is often associated with their transcriptional repression, yet the methylation of CpG islands located downstream of
promoters does not block transcription. We investigated the kinetics of
mRNA induction, demethylation, and remethylation of the p16
promoter and second-exon CpG islands in T24 cells after 5-aza-2'-deoxycytidine (5-Aza-CdR) treatment to explore the
relationship between CpG island methylation and gene transcription. The
rates of remethylation of both CpG islands were associated with time but not with the rate of cell division, and remethylation of the p16 exon 2 CpG island occurred at a higher rate than that
of the p16 promoter. We also examined the relationship
between the remethylation of coding sequence CpG islands and gene
transcription. The kinetics of remethylation of the p16
exon 2, PAX-6 exon 5, c-ABL exon 11, and
MYF-3 exon 3 loci were examined following 5-Aza-CdR
treatment because these genes contain exonic CpG islands which are
hypermethylated in T24 cells. Remethylation occurred most rapidly in
the p16, PAX-6, and c-ABL genes,
shown to be transcribed prior to drug treatment. These regions also
exhibited higher levels of remethylation in single-cell clones and
subclones derived from 5-Aza-CdR-treated T24 cells. Our data suggest
that de novo methylation is not restricted to the S phase of the cell
cycle and that transcription through CpG islands does not inhibit their remethylation.
 |
INTRODUCTION |
DNA methylation is essential for
normal embryonic development, possibly due to its roles in
transcriptional silencing (7, 32, 45, 50), X-chromosome
inactivation (41, 46), and genomic imprinting (10,
31). Cytosine methylation normally occurs at CpG dinucleotides,
which are represented at lower-than-expected frequencies in the
eukaryotic genome, with the exception of regions known as CpG islands,
which have the statistically expected frequency of CpGs
(12). Analyses of the spatial relationship between CpG islands and eukaryotic genes have shown that CpG islands often reside
within gene promoters and extend further downstream into transcribed
regions (5); however, they can also occur in regions remote
from the promoter (30). CpG islands normally remain
unmethylated in the germ line and rarely become methylated in somatic
cells (1); however, alterations in these methylation
patterns are associated with many human cancers (2, 4, 23).
Numerous investigations suggest that hypermethylation of promoter CpG
islands correlates with transcriptional inhibition (7, 13, 17-19,
39, 44, 47, 53). On the other hand, additional studies show that
de novo methylation of CpG islands residing within transcribed regions
is permissive for gene expression (22, 24, 54) and that
methylation of exonic CpG islands does not inhibit transcriptional
elongation in mammalian cells (14). Paradoxically,
hypermethylation of promoter CpG islands is often associated with
transcriptional silencing, whereas increased CpG island methylation
downstream of transcription initiation correlates with gene expression
(24).
Additional evidence from our laboratory suggests that gene
transcription does not block the de novo methylation of CpG islands, though most studies in the field have concentrated on the effects of
promoter methylation on gene silencing. First, genome-scanning techniques have led to the identification of CpG islands within transcribed regions of genes which are overexpressed and
hypermethylated in tumor cells (33, 48); second,
hypermethylation of p16 exon 2 has been observed in primary
tumors and tumor cell lines which express the gene (13); and
third, this report shows that remethylation of the p16 exon
2 CpG island after 5-aza-2'-deoxycytidine (5-Aza-CdR) treatment occurs
more rapidly than that of the p16 promoter CpG island.
These observations led us to investigate the roles of cell division and
gene transcription in DNA methylation to further clarify the
association between gene transcription and the remethylation of CpG
islands, including those within exonic sequences. First, we analyzed
the kinetics of p16 activation and demethylation by 5-Aza-CdR in the T24 bladder carcinoma cell line and observed that
demethylation of the p16 promoter CpG island was directly associated with transcription of the gene. Next, the rates of remethylation of the p16 gene following this transient
demethylation after 5-Aza-CdR treatment were shown to depend on time
but not on the rate of cell division, and it was shown that
p16 exon 2 became remethylated at a higher rate than the
promoter. We also explored how gene transcription might influence
remethylation of the coding sequence CpG islands in PAX-6
exon 5, c-ABL exon 11, and MYF-3 exon 3. Remethylation occurred most rapidly in the actively transcribed regions
of p16 exon 2, PAX-6 exon 5, and c-ABL
exon 11, whereas the MYF-3 gene, which is not transcribed in
T24 cells, exhibited a lower rate of remethylation than the other loci
examined. The transcribed CpG islands of p16 exon 2, PAX-6 exon 5, and c-ABL exon 11 also became
remethylated to greater degrees in clones and subclones derived from
T24 cells treated with 5-Aza-CdR, showing that the increased levels of
methylation observed were due to de novo methylation of previously
unmethylated sequences rather than to the selection of cells which had
been unaffected by treatment with a demethylating agent. These results show that cell division does not increase the rate of remethylation and
that the transcription of endogenous genes does not block remethylation of CpG islands.
 |
MATERIALS AND METHODS |
Cell lines.
The J82 and T24 bladder transitional cell
carcinoma cell lines were obtained from the American Type Tissue
Collection, Rockville, Md. T24 cells were cultured in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and
5% penicillin-streptomycin. J82 cells were cultured in minimal
essential medium supplemented with 10% FCS, 5%
penicillin-streptomycin, nonessential amino acids, and sodium pyruvate.
5-Aza-CdR treatments.
Cells were plated (3 × 105 cells per 100-mm dish) and treated 24 h later with
5-Aza-CdR (5 × 10
7 M). This dose was selected
because it exhibited the greatest effect on DNA demethylation with
minimal cytotoxicity. To increase the cell survival rate and facilitate
the isolation of single-cell clones, 3 × 10
7 M
5-Aza-CdR was utilized. The medium was changed 24 h after drug treatment and every 3 days subsequently. RNA and DNA were isolated after specific time periods following treatment, as described previously (13).
Analysis of the relationship between cell division and the de
novo methylation of CpG islands following 5-Aza-CdR treatment.
T24
cells originally maintained in DMEM containing 10% FCS and 5%
penicillin-streptomycin were plated (3 × 105 per
100-mm dish) in DMEM containing 1% FCS and 5%
penicillin-streptomycin. Cells were treated 24 h later with
5-Aza-CdR (5 × 10
7 M; Sigma Chemical Co., St.
Louis, Mo.). The drug was removed and the medium was replaced 24 h
after addition of the drug, with half the plates containing medium
supplemented with 1% FCS and the remaining half containing medium
supplemented with 10% FCS. The media were subsequently changed every 3 days. RNA and DNA were isolated after specific time periods following
treatment, as described previously (13). The total cell
number was assessed at each time point by using a Coulter Counter to
determine the differences in doubling times between cells grown in
medium supplemented with 1% FCS and those grown in 10% FCS.
Generation of T24 single-cell clones and subclones.
Cells
were plated (105 per 75-cm2 flask) and treated
24 h later with 5-Aza-CdR (3 × 10
7 M). This
lower dose was selected (instead of 5 × 10
7 M) to
reduce the immediate cytotoxic effects of the drug and increase the
cell survival rate, thus facilitating the isolation of individual
cells. Clones 2, 3, 4, and 7 were isolated from single cells between 48 and 72 h after drug removal, as described previously
(14). Conditioned medium was used for the initial culturing
of single-cell clones. One of these clones (clone 4) was used for the
repeated isolation of single-cell subclones (designated 4:1, 4:2, 4:5,
and 4:9). RNA and DNA were extracted from each individual clone or
subclone at least 20 cell population doublings after isolation.
Quantitation of methylation by Ms-SNuPE.
Methylation of
PAX-6 exon 5, c-ABL exon 11, MYF-3
exon 3, p16 exon 2, and the p16 promoter was
measured by the methylation-sensitive single nucleotide primer
extension (Ms-SNuPE) assay as described previously (15). T24
cells were treated with 5-Aza-CdR (5 × 10
7 M), and
DNA was harvested at various times after treatment (proteinase K
digestion, phenol-chloroform extraction, and ethanol precipitation). DNA was also isolated from T24 single-cell subclones. Genomic DNA was
treated with sodium bisulfite (8, 11) to convert unmethylated cytosines to uracil, leaving 5-methylcytosine unchanged. The regions of interest were amplified with PCR primers specific for
bisulfite-converted DNA (Table 1). The
PCR conditions were as follows: for the p16 promoter, 95°C
for 3 min, 37 cycles of 95°C for 50 s, 67°C for 50 s, and
72°C for 45 s, and 72°C for 2 min; for p16 exon 2, 95°C for 3 min, 38 cycles of 95°C for 50 s, 60°C for 50 s, and 72°C for 45 s, and 72°C for 2 min; for PAX-6 exon 5, 95°C for 3 min, 38 cycles of 95°C for 1 min, 50°C for 30 s, and 72°C for 1 min, and 72°C for 2 min; for
c-ABL exon 11, 95°C for 3 min, 37 cycles of 95°C for
50 s, 47°C for 50 s, and 72°C for 45 s, and 72°C
for 2 min; and for MYF-3 exon 3, 95°C for 3 min, 36 cycles
of 95°C for 50 s, 49°C for 40 s, and 72°C for 45 s, and 72°C for 2 min. SNuPE was performed with primers internal to
the region amplified, with each primer terminating immediately 5' of
the CpG site to be assayed. The methylation status of individual CpG
sites within the amplified regions of interest was analyzed, and the
average methylation value for two or three sites within each region was
obtained. Ms-SNuPE sequences specific for each region are shown in
Table 1. The conditions for primer extension were as follows: for the
p16 promoter and exon 2, 95°C for 2 min, 50°C for 1 min,
and 72°C for 1 min; for PAX-6 exon 5, 95°C for 2 min,
60°C for 1 min, and 72°C for 1 min; for c-ABL exon 11, 95°C for 2 min, 47°C for 2 min, and 72°C for 1 min; and for
MYF-3 exon 3, 95°C for 2 min, 43°C for 1 min, and 72°C
for 1 min.
RT-PCR.
Total RNA was isolated from 2 × 106 cells lysed in 2 ml of buffer containing guanidine
isothiocyanate (4 M; Gibco BRL, Palo Alto, Calif.), N-lauryl
sarcosine (0.5%), sodium citrate (25 mM; Fisher Scientific, Fair Lawn,
N.J.), and 2-mercaptoethanol (0.1 M; Sigma Chemical Co.). RNA was
precipitated (1 h,
20°C) in 50% isopropanol-50% lysis buffer
following standard phenol-chloroform extraction of the cell lysate.
After centrifugation (10 min, 10,000 × g), the
supernatant was decanted and the RNA pellet was washed twice in 70%
ethanol prepared with diethylpyrocarbonate-treated double-distilled
water. The RNA pellet was dissolved in 100%
diethylpyrocarbonate-treated water. Two micrograms of total RNA was
reverse transcribed with random hexamers, deoxynucleoside
triphosphates, and SuperScript II reverse transcriptase (Gibco BRL) in
a 25-µl reaction mixture, as described previously (13).
cDNA was amplified with primers specific for either PAX-6,
c-ABL, MYF-3, p16, or
GAPDH. PCR primer sequences and conditions for
p16 and GAPDH were utilized as described previously (13). The primer sequences for PAX-6,
c-ABL, and MYF-3 expression analysis are listed
in Table 1. The reverse transcription (RT)-PCR conditions were as
follows: for PAX-6, 95°C for 3 min, 30 cycles of 95°C
for 1 min, 60°C for 30 s, and 72°C for 1 min, and 72°C for 2 min; for c-ABL, 95°C for 3 min, 28 cycles of 95°C
for 50 s, 60°C for 50 s, and 72°C for 45 s, and
72°C for 2 min; and for MYF-3, 95°C for 3 min, 27 cycles of 95°C for 1 min, 58°C for 45 s, and 72°C for
45 s, and 72°C for 2 min. PCRs were performed with cDNA template
concentrations equivalent to 100 ng of RNA. All reactions were analyzed
in the linear range of amplification. PCR products were resolved on 2%
agarose gels and subsequently transferred to nylon membranes
(Zetaprobe; Bio-Rad, Richmond, Calif.) under alkaline conditions. All
blots were hybridized with digoxigenin-labeled oligonucleotide probes
(Genius; Boehringer, Mannheim, Germany).
Determination of cytotoxicity.
T24 cells (200 per 60-mm
dish) were plated in triplicate sets for a colony formation assay.
Cells were treated with 10
7, 5 × 10
7,
or 10
6 M 5-Aza-CdR 24 h later. Once cell colonies
were visible (after 7 days), cells were fixed in 100% methanol and
stained with 10% Giemsa stain. The cell survival percentage was
assessed by dividing the mean colony number on the 5-Aza-CdR-treated
plates by the mean colony number on the untreated plates and
multiplying the quotient by 100. This number was subtracted from 100 to
determine the percent toxicity.
 |
RESULTS |
Kinetics of p16 mRNA induction and p16
promoter demethylation by 5-Aza-CdR in T24 cells.
Members of our
group have previously shown that activation of the p16 gene
by 5-Aza-CdR in the T24 bladder carcinoma cell line is associated with
significant demethylation of the p16 promoter CpG island
(3, 14). The kinetics of p16 mRNA induction and p16 promoter demethylation were studied with precision by
the quantitative Ms-SNuPE assay (15) to determine the
relationship between these two processes (Fig.
1a). Preliminary experiments (data not
shown) demonstrated that the concentration of 5-Aza-CdR most effective
at inducing p16 expression and at reducing p16 methylation with minimal toxicity was 5 × 10
7 M. p16 expression was detected beginning 36 h after
treatment of T24 cells with 5-Aza-CdR. The kinetics of demethylation
within the proposed critical region of the p16 promoter
(14) were investigated in parallel by the quantitative
Ms-SNuPE technique (Fig. 1b and c). Reduced methylation was first
apparent after 36 h (Fig. 1c). Maximal demethylation was detected
between 48 and 72 h, with average methylation values of 36 and
35%, respectively, and the average methylation value increased to 52%
by 96 h after treatment (Fig. 1c). These results support recent
studies of the roles of critical CpG sites in the p16
promoter, whose hypermethylation is associated with transcriptional
silencing (14), and they indicate that demethylation of this
region by 5-Aza-CdR may play a direct role in drug-mediated mRNA
p16 induction. The data are also important for our future
quantitative studies, which will describe the kinetics of remethylation
following maximal demethylation after 72 h.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of p16 mRNA induction and promoter
demethylation by 5-Aza-CdR. T24 cells were exposed to 5-Aza-CdR (5 × 10 7 M) for 24 h. DNA and RNA were isolated at
12-h intervals after drug addition. (a) Levels of p16 mRNA
expression at each time point were determined by RT-PCR analysis.
Relative levels of GAPDH mRNA expression were measured to
control for relative cDNA input. PCR products were resolved on 2%
agarose, transferred to a nylon membrane, and hybridized with an
internal oligonucleotide probe specific for the cDNA sequence of either
p16 or GAPDH. (b) Schematic map of the
p16 5' CpG island. A 149-bp region (hatching) was amplified
by PCR with primers specific for bisulfite-converted DNA (raised
horizontal bars), and three CpG sites were analyzed by the Ms-SNuPE
technique (sites A, B, and C). Each tick mark represents an individual
CpG dinucleotide, and the arrows show putative transcription initiation
sites. (c) Demethylation of the p16 promoter by 5-Aza-CdR at
each time point, quantitated by Ms-SNuPE. Ms-SNuPE reaction mixtures
were resolved on a 16% denaturing polyacrylamide gel and subsequently
exposed by autoradiography, using purified bisulfite PCR products as
the templates for primer extension. The presence of a band indicates
primer extension at a given CpG site. A band in the "C" lane
indicates the detection of DNA molecules which are methylated, and a
band in the "T" lane indicates the detection of unmethylated
molecules.
|
|
Model for the mechanism of p16 promoter demethylation
by 5-Aza-CdR.
Figure 2 illustrates
the kinetics of demethylation expected to result from the incorporation
of 5-Aza-CdR into replicating, hypermethylated DNA. Hemimethylated
duplex DNAs prepared from cells treated with 5-Aza-CdR present
favorable substrates for DNA methyltransferase (27, 40, 51),
and the dose used (5 × 10
7 M) has been shown to
inhibit DNA methyltransferase almost completely and to deplete cells of
active enzyme upon incorporation into a CpG site opposite a methylated
CpG (26, 51). T24 cells would enter one or two S phases
during the 24-h treatment with 5-Aza-CdR because the drug has no
immediate effect on the cells' division, and members of our group
confirmed a doubling time of 21 h in treated and untreated cells,
as previously described (3). The "active" inhibitor of
DNA methyltransferase is present in hemimethylated DNA up to
48 h after treatment, and maintenance methylase activity is
expected to methylate its hemimethylated substrate after 72 h,
assuming that recovery synthesis of the DNA methyltransferase has
occurred (51). Consistent with this model, it has been
demonstrated by bisulfite sequencing that 5-Aza-CdR incorporation into
replicating DNA results in the formation of individual DNA molecules in
the p16 promoter containing patches of demethylation
spanning 200 to 400 bp (14).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Model for the mechanism of DNA demethylation by
5-Aza-CdR. Unsynchronized T24 cells in the log phase of growth have a
doubling time of 21 h (3) and were treated with
5-Aza-CdR (5 × 10 7 M) for 24 h. DNA and RNA
were isolated at 24-h intervals, p16 promoter methylation
levels were quantitated by Ms-SNuPE, and the presence of p16
mRNA was determined by RT-PCR. Cell numbers were assessed at each time
point to determine the cell population doubling time. Strand breakage
of 5-Aza-CdR-containing DNA after bisulfite treatment is likely because
of the lability of the drug under alkaline conditions, which explains
why the observed and expected values for methylation differ. Methylated
CpG sites are indicated by black circles, DNA strands containing
incorporated 5-Aza-CdR are each indicated by an outlined letter
"Z," and horizontal arrows show sites of hemimethylated DNA where
maintenance methylation is expected to occur.
|
|
The methylation values quantitated for the
p16 promoter
after 5-Aza-CdR treatment were higher than expected. One explanation
is
that the Ms-SNuPE technique entails sodium bisulfite treatments
under
alkaline conditions, which would facilitate the rapid hydrolysis
and
breakage of 5-Aza-CdR-containing DNA strands due to the analog's
lability in alkaline solutions (
9). The
p16
promoter methylation
values were consistent with a model for the
activity of 5-Aza-CdR
which assumes that the 5-Aza-CdR-containing DNA
molecules, fragmented
upon exposure to sodium bisulfite, should not
contribute to the
measured methylation levels. This technical bias
against measuring
the methylation status of analog-containing molecules
becomes
less significant during subsequent rounds of DNA replication
after
drug
removal.
Figure
2 further elucidates the association between drug-induced
p16 promoter demethylation and the reactivation of
p16 mRNA
expression. The data are consistent with previous
analyses of
clones of T24 cells treated with 5-Aza-CdR, where efficient
p16 mRNA expression was observed in clones with extensive
demethylation
of the
p16 promoter (
14). They also
suggest that
p16 transcription
was not initiated from a
hemimethylated promoter template, because
no
p16 mRNA was
detected 24 h after treatment. It is likely that
the sequence must
become demethylated on both DNA strands to facilitate
p16
transcription; however, additional experiments must be performed
to
address this
issue.
Role of cell division in remethylation of p16.
p16
promoter methylation is restored to original levels during passage in
culture following 5-Aza-CdR treatment, with complete remethylation after 21 population doublings associated with
decreased p16 mRNA expression and restoration of the
doubling time to the same as that of untreated cells (3).
Thus, we investigated whether remethylation of the promoter and exon 2 CpG islands followed similar kinetics and whether their rates of
remethylation would be influenced by the rate of cell division. Figure
3 illustrates the relationship between
time and the remethylation of the two CpG islands of p16 in
T24 cells after 5-Aza-CdR treatment. Interestingly, cells grown in 1 and 10% FCS exhibited nearly identical kinetics of p16
remethylation, although their growth characteristics differed significantly. The CpG island in exon 2 also remethylated at a higher
rate than the promoter under both growth conditions, and the rate of
cell division after drug treatment had no effect on the rate of
remethylation of either CpG island. For example, the two islands had
become similarly remethylated 25 days after treatment, even though
cells grown in 1% FCS had undergone only 2.5 population doublings,
versus 10 population doublings for cells cultured in 10% FCS. The CpG
island in exon 2 also became completely remethylated over a 2-week
period if treated cells were arrested in G1 by culturing them in medium containing 0.1% serum immediately after treatment. This
resulted in an almost complete loss of histone H4 mRNA, whose expression is restricted to S phase (data not shown). These results suggest that the remethylation of CpG islands after drug-induced demethylation is a time-dependent but not a cell division-dependent process and can occur in the G1 phase of the cell cycle.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Investigation of the association between the rate of
cell division and the rate of remethylation. T24 cells treated with
5-Aza-CdR (5 × 10 7 M) were maintained in medium
supplemented with either 1 or 10% FCS. DNA was isolated at specific
times after 5-Aza-CdR treatment and subsequently treated with sodium
bisulfite (8, 11). Methylation of the p16
promoter (p16 Pro.) and exon 2 (p16 Ex. 2) CpG
islands was determined by Ms-SNuPE (15) before and after
5-Aza-CdR treatment to ascertain whether remethylation of these regions
was associated with the rate of cell division. Remethylation was
determined as the degree of recovery (compared to original levels)
following maximal demethylation at 72 h. T24 cells grown in medium
supplemented with 10% FCS were analyzed as controls. If de novo
methylation of p16 is linked to the rate of cell division,
then cells maintained in 10% FCS would be expected to remethylate
p16 more rapidly than cells dividing more slowly in 1%
FCS.
|
|
Kinetics of p16, PAX-6, c-ABL,
and MYF-3 remethylation in T24 cells after 5-Aza-CdR
treatment.
We further investigated the effects of gene
transcription on the remethylation of CpG islands downstream from the
region of transcription initiation to possibly explain why the
p16 promoter became remethylated more slowly than
p16 exon 2 (Fig. 3). The remethylation kinetics of the
p16 exon 2, PAX-6 exon 5, c-ABL exon
11, and MYF-3 exon 3 CpG islands were examined because these islands are hypermethylated in T24 cells, they reside within coding sequences, and they become significantly demethylated by 5-Aza-CdR in
vitro (Fig. 4). Levels of demethylation
were measured beginning 72 h after drug addition because maximal
demethylation has been observed in most loci examined at this time
point. The levels of p16, PAX-6,
c-ABL, and MYF-3 transcription were determined by
RT-PCR in the same cells. Transcription of p16,
PAX-6, and c-ABL was detected in T24 cells both
before and after 5-Aza-CdR treatment; however, MYF-3 was not
transcribed in either case. The remethylation kinetics of the
p16 exon 2, PAX-6 exon 5, c-ABL exon
11, and MYF-3 exon 3 CpG islands were analyzed by Ms-SNuPE in T24 cells treated with 5-Aza-CdR (Fig.
5). All the loci examined showed
significant remethylation between 3 and 7 days after 5-Aza-CdR treatment; however, the methylation levels of the p16 exon
2, PAX-6 exon 5, and c-ABL exon 11 CpG islands
continued to increase for up to 27 days, whereas the methylation levels
of MYF-3 exon 3 remained constant. One explanation for this
observation is that the absence of MYF-3 transcription
somehow prevents remethylation of this gene. Alternatively, these data
are consistent with the hypothesis that transcription does not block
remethylation of endogenous genes because the loci which were
transcribed demonstrated higher rates of remethylation than
the MYF-3 gene, which was not transcribed (Fig. 5).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of 5-Aza-CdR on the demethylation and
transcription of the p16 promoter and exon 2, PAX-6 exon 5, c-ABL exon 11, and MYF-3
exon 3 in T24 cells. Average methylation values for specific sites
within the p16, PAX-6, c-ABL, and
MYF-3 exonic CpG islands were measured in T24 cells prior to
drug treatment (black bars) and 72 h after treatment with 5 × 10 7 M 5-Aza-CdR (white bars). Error bars indicate the
ranges of values obtained. Relative transcription levels of each gene
were also estimated by comparison of band intensities ( , +, or ++)
before and after drug treatment by RT-PCR analysis (data not shown).
The CpG and GC contents of these regions were also analyzed to
determine if these exonic sequences fulfilled the criteria of CpG
islands in which a DNA sequence of 200 bp must have a GC content of
0.50 and an observed/expected CpG ratio of 0.60 (12).
Fragments of 800 bp from each gene, all of which fulfilled the
established criteria for CpG islands, were analyzed. In untreated T24
cells, transcription through the p16 promoter and exon 2 CpG
islands is not initiated from the p16 promoter but is
initiated from the upstream p14 promoter (38).
Pro., promoter.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
Remethylation kinetics of CpG islands in T24 cells after
5-Aza-CdR treatment. T24 cells were treated with 5-Aza-CdR (5 × 10 7 M), and DNA was harvested every 1 to 3 days for up to
27 days. The population doubling time increased approximately 1.8-fold
after 5-Aza-CdR treatment, as previously described (3). Only
eight cell population doublings were attained between days 3 and 27 because cells transiently entered lag phase each time they were split
and reseeded. Methylation of p16 exon 2, PAX-6
exon 5, c-ABL exon 11, and MYF-3 exon 3 was
quantitated at each time point by the Ms-SNuPE technique, and the
degree of remethylation at each locus was determined as the degree of
methylation compared to the original level in untreated cells at
72 h. Methylation averages from three independent experiments are
shown.
|
|
Relationship between gene transcription and the
remethylation of downstream CpG islands in clones and
subclones derived from T24 cells.
Methylation levels within
p16, PAX-6, c-ABL, and
MYF-3 were quantitated in clones derived from single T24
cells after 5-Aza-CdR treatment (clones 2, 3, 4, and 7) to determine
whether the remethylation observed (Fig. 5) resulted from de novo
methylation or from the selection of cells in which CpG islands had not
become demethylated by the drug (Fig. 6).
Four additional subclones derived from clone 4 were also analyzed
(subclones 4:1, 4:2, 4:5, and 4:9). The p16 promoter and
exon 2 regions showed complete remethylation in clone 2, which does not
express p16 (14). Remethylation of both CpG islands was also more apparent in clone 2 (Fig. 6) than in clones 3, 7, and 4, which expressed p16 at increasing levels
(14). It is possible that clone 2 resulted from the
selection of cells in which p16 never became demethylated by
5-Aza-CdR. Clones 7 and 4 showed less remethylation of exon 2 than
clone 3. This does not disprove the hypothesis that transcription does
not block de novo methylation, however, because the p16 gene
sequence is transcribed as part of the p14 gene transcript
initiating from the upstream p14 promoter (38) in
all eight clones and subclones (reference 15 and
data not shown). Another explanation is that p16 exon 2 did
not become demethylated by 5-Aza-CdR in clone 3. The subclones derived
from clone 4 (4:1, 4:2, 4:5, and 4:9) showed complete
remethylation of p16 exon 2, while evidence for
de novo methylation of the p16 promoter was demonstrated in
subclones 4:1, 4:5, and 4:9. These clones and subclones were derived
from individual parental cells, and the methylation results clearly demonstrated that de novo methylation rather than selection occurred in
these cells. Whether this methylation is due to spreading of methylation from a few sites left unaffected by 5-Aza-CdR or is the
same process as that responsible for de novo methylation of completely
unmodified sequences is not clear.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Remethylation of CpG islands after 5-Aza-CdR treatment
in T24 clones and subclones. Clones 2, 3, 4, and 7 were isolated
following treatment of parent T24 cultures with 5-Aza-CdR (3 × 10 7 M). This lower dose was utilized (instead of 5 × 10 7 M) to increase the cell survival rate and to
facilitate the isolation of the clones. Clone 4 was used for the
repeated isolation of single-cell subclones. DNA was isolated, and
methylation of the p16 promoter, p16 exon 2, PAX-6 exon 5, c-ABL exon 11, and MYF-3
exon 3 CpG islands was quantitated by Ms-SNuPE. Clones 2, 3, 4, and 7 completed approximately 20 cell population doublings at the time DNA
was harvested, whereas subclones derived from clone 4 (4:1, 4:2, 4:5,
and 4:9) completed approximately 40 population doublings (data not
shown). The degree of remethylation at each locus was determined as the
degree of methylation recovery (compared to original levels) following
maximal demethylation at 72 h. Methylation averages from three
independent experiments are shown.
|
|
All clones and subclones expressed
c-ABL and
PAX-6 (data not shown). Complete remethylation of
c-ABL exon 11 was observed
in all but subclone 4:9, and
remethylation of
PAX-6 exon 5 varied
significantly (from 40 to 88%) among all eight clones and subclones
(Fig.
6). The
MYF-3 exon 3 CpG island, which was not transcribed
in any of
the clones or subclones (data not shown), demonstrated
significant
remethylation only in clone 3 and subclone 4:9. Increased
methyltransferase expression in these two cases may be responsible
for
this clonal variation in methylation levels. Alternatively,
transcription may facilitate but not be required for de novo
methylation.
Altogether, these results have revealed (i) that de
novo methylation
of CpG islands occurs in T24 cells after 5-Aza-CdR
treatment,
(ii) that the observed methylation patterns show clonal
variability,
and (iii) that gene transcription may be associated with
the remethylation
of CpG islands within the transcribed regions of
genes.
 |
DISCUSSION |
CpG islands frequently reside within promoter regions and extend
downstream into the transcribed regions of genes (5, 30), and it has been widely documented that hypermethylation of promoter sequence CpG islands causes transcriptional repression (7, 13,
17-19, 39, 44, 47, 53). We investigated the roles of cell
division and gene transcription in the remethylation of CpG islands
within the p16 promoter, p16 exon 2, and the
coding sequences of several additional genes. Our results show that the rate of DNA remethylation is not associated with the rate of cell division and that hypermethylation of CpG islands downstream of promoter sequences does not block transcription initiation and elongation.
Quantitative analyses showed that the kinetics of demethylation of the
p16 promoter were directly associated with the activation of
p16 mRNA, consistent with previous investigations of
critical CpGs in the p16 promoter, where hypermethylation is
associated with transcriptional silencing (14).
Demethylation of the promoter may directly mediate p16 mRNA
induction by 5-Aza-CdR; however, factors associated with demethylation
could also include chromatin decondensation, changes in protein-DNA
interactions, or activation in trans. The results also
demonstrate the utility of the Ms-SNuPE technique (15), with
which minimal CpG demethylation within the p16 promoter
could be reliably measured. Thus, the sensitivity of this assay allowed
us to investigate remethylation of p16 as a function of time
in more detail. The fact that the kinetics of remethylation of the
p16 gene were not influenced by the number of cell divisions
after treatment was interesting in view of the fact that levels of the
DNA methyltransferase I (Dnmt 1) mRNA are known to vary in the cycle
and to be increased in S-phase cells (49). It is therefore
possible that the remethylation observed may be catalyzed by one of the
newly isolated putative methyltransferase enzymes Dnmt 3a and 3b
(43), which may not show such cell cycle regulation.
Our results also showed that the p16 exon 2 CpG island
became remethylated more rapidly than the p16 promoter CpG
island after drug treatment. One explanation for this observation is
that protein-DNA interactions within the p16 promoter but
not exon 2 interfered with remethylation of this region subsequent to
drug treatment (see Fig. 7). This prediction is consistent with studies
by Macleod et al. (35, 36) and Brandeis et al.
(6), who showed that mutagenesis of Sp1 sites within the CpG
islands of the mouse and hamster aprt promoters,
respectively, resulted in the de novo methylation of these sequences.
Sp1 elements were therefore implicated in the prevention of methylation
spreading, and Macleod et al. (35, 36) have proposed that
the presence of a functional promoter at the 5' end of a CpG island
maintains its methylation-free status. Alternatively, Brandeis et al.
(6) suggested that protein-occupied Sp1 sites in the hamster
aprt promoter prevent methylation spreading by
"protecting" CpGs from methylation. With regard to this model, it
is possible that transcription factors associated with regions of the
p16 promoter protect it from methylation following
demethylation by 5-Aza-CdR. This is indirectly supported by analyses of
p16 promoter methylation in single-cell T24 clones, which
revealed a localized patch of demethylation induced by 5-Aza-CdR within a region containing putative transcription initiation sites
(14). Additional experiments must be performed to identify
factors which possibly bind to this region, block methylation and
prevent further spreading of the patch.
The model in Fig. 7 illustrates how
promoter and coding sequence CpG islands of a growth-regulatory gene
(like p16) may become de novo methylated at different rates
after 5-Aza-CdR treatment in vitro. Following 5-Aza-CdR-mediated
demethylation and transcriptional activation, remethylation may first
appear in CpG islands located downstream of promoter sequences because
transcription factors bound to a demethylated promoter protect it from
methylation (6, 25). Cells which do acquire promoter
methylation may subsequently be selected by the acquisition of a
selective growth advantage due to methylation-coupled "resilencing"
of growth-regulatory genes (3, 23).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
Model for the remethylation of promoter and coding
sequence CpG islands of the p16 gene after 5-Aza-CdR
treatment. Promoter and coding sequence CpG islands of
growth-regulatory genes such as p16 become remethylated at
different rates after 5-Aza-CdR treatment. Following 5-Aza-CdR-mediated
demethylation and transcriptional activation, remethylation may first
appear in a CpG island downstream of the promoter, whereas
transcription factors (TF) associated with a demethylated promoter CpG
island protect it from remethylation. Patches of demethylation have
been observed by bisulfite genomic sequencing of the p16
promoter in single-cell clones after 5-Aza-CdR treatment, providing
support for this interpretation (14). Cells which acquire
promoter methylation in one or more growth-regulatory genes may
subsequently exhibit selective growth advantages due to the obstruction
of transcription factor binding, leading to gene silencing. The
protection of demethylated promoter sequences by transcription factors
may explain how exonic CpG islands can become remethylated more rapidly
than promoter islands after 5-Aza-CdR treatment, as DNA-binding
proteins may protect promoter sequences from methylation. Methylated
CpG sites are depicted as filled circles; unmethylated sites are shown
as open circles.
|
|
The relative sizes and CpG densities of the p16 promoter and
exon 2 CpG islands may also explain why transcription was associated with the increased rate of remethylation of exon 2. These
characteristics of CpG islands have been proposed to influence
transcriptional repression more than their relative positions within
genes (20, 21). Based on this theory, hypermethylation of a
smaller CpG island with fewer CpGs should have a lesser effect on
transcriptional repression than a larger island with a higher CpG
density. However, the higher rate of remethylation of p16
exon 2 associated with gene expression was probably not due to a
significantly smaller size and/or fewer CpGs in p16 exon 2, because the promoter and exon 2 CpG islands have similar CpG densities,
with the p16 exon 2 island spanning a region approximately
20% smaller than the promoter CpG island (data not shown).
Recent studies by Wutz et al. (52) have demonstrated that
methylation of the intronic CpG island of the maternal copy of the
mouse insulin-like growth factor 2 receptor gene (Igf2r) was associated with its expression. This region, which serves as a promoter
for transcription in the opposite direction, was unmethylated in the
paternal copy, correlating with methylation of the upstream CpG island
of Igf2r. Additionally, CpG sites in the hypoxanthine phosphoribosyltransferase gene on the active X chromosome are more
methylated than those on the inactive allele (34). These observations, in addition to our studies of p16 exon 2, PAX-6 exon 5, and c-ABL exon 11, are consistent
with a role for transcription in the de novo methylation of CpG islands
downstream of gene promoters. Nevertheless, transcription is probably
not always required for methylation, because CpG islands within the
coding sequences of transcribed genes are often unmethylated in
eukaryotic cells (24). Transcription-coupled mechanisms
which may facilitate methylation of CpG islands include helical
unwinding and/or DNA strand separation by presenting DNA substrates
more accessible and favorable for de novo methylation. Additional
molecular processes or conditions which may further influence de novo
methylation include the following activities: protein-DNA interactions
(6, 35, 36), chromatin decondensation and structural changes
associated with replication (1, 25, 29), histone
deacetylation (28, 42), or the proximity of Alu
sequences to certain CpG islands (16, 37). Our studies raise
the intriguing question of whether there is a causal link between
transcription and the de novo methylation of CpG islands; thus, the
association between these processes requires further examination.
 |
ACKNOWLEDGMENTS |
We thank Gangning Liang for his assistance with the figures and
TuDung Nguyen for detailing the primer sequences and reaction conditions for PCR-based amplification of the c-ABL gene.
This work was supported by USPHS grant R37 CA49758 from the National
Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Urologic
Research Laboratory, USC/Norris Comprehensive Cancer Center, University
of Southern California School of Medicine, 1441 Eastlake Ave., Rm. 8302L, Los Angeles, CA 90089-9181. Phone: (323) 865-0816. Fax: (323)
865-0102. E-mail: jones_p{at}froggy.hsc.usc.edu.
 |
REFERENCES |
| 1.
|
Antequera, F.,
J. Boyes, and A. Bird.
1990.
High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines.
Cell
62:503-514[Medline].
|
| 2.
|
Baylin, S. B.,
J. G. Herman,
J. R. Graff,
P. M. Vertino, and J.-P. Issa.
1998.
Alterations in DNA methylation: a fundamental aspect of neoplasia.
Adv. Cancer Res.
72:141-146[Medline].
|
| 3.
|
Bender, C. M.,
M. M. Pao, and P. A. Jones.
1998.
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Cancer Res.
58:95-101[Abstract/Free Full Text].
|
| 4.
|
Bender, C. M.,
J. M. Zingg, and P. A. Jones.
1998.
DNA methylation as a target for drug design.
Pharmacol. Res.
15:175-187.
|
| 5.
|
Bird, A. P.
1987.
CpG islands as gene markers in the vertebrate nucleus.
Trends Genet.
3:342-347.
|
| 6.
|
Brandeis, M.,
D. Frank,
I. Keshet,
Z. Siegfried,
M. Mendelsohn,
A. Nemes,
V. Temper,
A. Razin, and H. Cedar.
1994.
Sp1 elements protect a CpG island from de novo methylation.
Nature
371:435-438[Medline].
|
| 7.
|
Cedar, H.,
R. Stein,
Y. Gruenbaum,
T. Naveh-Many,
N. Sciaky-Gallili, and A. Razin.
1983.
Effect of DNA methylation on gene expression.
Cold Spring Harbor Symp. Quant. Biol.
47:605-609.
|
| 8.
|
Clark, S. J.,
J. Harrison,
C. L. Paul, and M. Frommer.
1994.
High sensitivity mapping of methylated cytosines.
Nucleic Acids Res.
22:2990-2997[Abstract/Free Full Text].
|
| 9.
|
Constantinides, P. G.,
P. A. Jones, and W. Gevers.
1977.
Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment.
Nature
267:364-366[Medline].
|
| 10.
|
Ferguson-Smith, A. C.,
H. Sasaki,
B. M. Cattanach, and M. A. Surani.
1993.
Parental origin-specific epigenetic modification of the mouse H19 gene.
Nature
362:751-755[Medline].
|
| 11.
|
Frommer, M.,
L. E. McDonald,
D. S. Millar,
C. M. Collis,
F. Watt,
G. W. Grigg,
P. L. Molloy, and C. L. Paul.
1992.
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.
Proc. Natl. Acad. Sci. USA
89:1827-1831[Abstract/Free Full Text].
|
| 12.
|
Gardiner-Garden, M., and M. Frommer.
1987.
CpG islands in vertebrate genomes.
J. Mol. Biol.
196:261-282[Medline].
|
| 13.
|
Gonzalez-Zulueta, M.,
C. M. Bender,
A. S. Yang,
T. Nguyen,
R. W. Beart,
J. M. Van Tornout, and P. A. Jones.
1995.
Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Cancer Res.
55:4531-4535[Abstract/Free Full Text].
|
| 14.
|
Gonzalgo, M. L.,
T. Hayashida,
C. M. Bender,
M. M. Pao,
Y. C. Tsai,
F. A. Gonzales,
H. D. Nguyen,
T. T. Nguyen, and P. A. Jones.
1998.
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Cancer Res.
58:1245-1252[Abstract/Free Full Text].
|
| 15.
|
Gonzalgo, M. L., and P. A. Jones.
1997.
Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE).
Nucleic Acids Res.
25:2529-2531[Abstract/Free Full Text].
|
| 16.
|
Graff, J. R.,
J. G. Herman,
S. Myohanen,
S. B. Baylin, and P. M. Vertino.
1997.
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation.
J. Biol. Chem.
272:22322-22329[Abstract/Free Full Text].
|
| 17.
|
Herman, J. G.,
J. Jen,
A. Merlo, and S. B. Baylin.
1996.
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Cancer Res.
56:722-727[Abstract/Free Full Text].
|
| 18.
|
Herman, J. G.,
F. Latif,
Y. Weng,
M. I. Lerman,
B. Zbar,
S. Liu,
D. Samid,
D. S. Duan,
J. R. Gnarra, and W. M. Linehan.
1994.
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Proc. Natl. Acad. Sci. USA
91:9700-9704[Abstract/Free Full Text].
|
| 19.
|
Herman, J. G.,
A. Merlo,
L. Mao,
R. G. Lapidus,
J. P. Issa,
N. E. Davidson,
D. Sidransky, and S. B. Baylin.
1995.
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Cancer Res.
55:4525-4530[Abstract/Free Full Text].
|
| 20.
|
Hsieh, C.-L.
1994.
Dependence of transcriptional repression on CpG methylation density.
Mol. Cell. Biol.
14:5487-5494[Abstract/Free Full Text].
|
| 21.
|
Hsieh, C.-L.
1997.
Stability of patch methylation and its impact in regions of transcriptional initiation and elongation.
Mol. Cell. Biol.
17:5897-5904[Abstract].
|
| 22.
|
Issa, J. P.,
P. M. Vertino,
C. D. Boehm,
I. F. Newsham, and S. B. Baylin.
1996.
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis.
Proc. Natl. Acad. Sci. USA
93:11757-11762[Abstract/Free Full Text].
|
| 23.
|
Jones, P. A.
1996.
DNA methylation errors and cancer.
Cancer Res.
56:2463-2467[Free Full Text].
|
| 24.
|
Jones, P. A.
1999.
The DNA methylation paradox.
Trends Genet.
15:34-37[Medline].
|
| 25.
|
Jones, P. A., and P. W. Laird.
1999.
Cancer epigenetics comes of age.
Nat. Genet.
21:163-167[Medline].
|
| 26.
|
Jones, P. A., and S. M. Taylor.
1980.
Cellular differentiation, cytidine analogs and DNA methylation.
Cell
20:85-93[Medline].
|
| 27.
|
Jones, P. A., and S. M. Taylor.
1981.
Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells.
Nucleic Acids Res.
9:2933-2947[Abstract/Free Full Text].
|
| 28.
|
Jones, P. L.,
G. J. Veenstra,
P. A. Wade,
D. Vermaak,
S. U. Kass,
N. Landsberger,
J. Strouboulis, and A. P. Wolffe.
1998.
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.
Nat. Genet.
19:187-191[Medline].
|
| 29.
|
Kass, S. U.,
J. P. Goddard, and R. L. Adams.
1993.
Inactive chromatin spreads from a focus of methylation.
Mol. Cell. Biol.
13:7372-7379[Abstract/Free Full Text].
|
| 30.
|
Larsen, F.,
G. Gundersen,
R. Lopez, and H. Prydz.
1992.
CpG islands as gene markers in the human genome.
Genomics
13:1095-1107[Medline].
|
| 31.
|
Li, E.,
C. Beard, and R. Jaenisch.
1993.
Role for DNA methylation in genomic imprinting.
Nature
366:362-365[Medline].
|
| 32.
|
Li, E.,
T. H. Bestor, and R. Jaenisch.
1992.
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality.
Cell
69:915-926[Medline].
|
| 33.
|
Liang, G.,
C. E. Salem,
M. C. Yu,
H. D. Nguyen,
F. A. Gonzales,
T.-D. T. Nguyen,
P. W. Nichols, and P. A. Jones.
1998.
DNA methylation differences associated with tumor tissues identified by genome scanning analysis.
Genomics
53:260-268[Medline].
|
| 34.
|
Lock, L. F.,
D. W. Melton,
C. T. Caskey, and G. R. Martin.
1986.
Methylation of the mouse hprt gene differs on the active and inactive X chromosomes.
Mol. Cell. Biol.
6:914-924[Abstract/Free Full Text].
|
| 35.
|
Macleod, D.,
R. R. Ali, and A. Bird.
1998.
An alternative promoter in the mouse major histocompatibility complex class II I-A gene: implications for the origin of CpG islands.
Mol. Cell. Biol.
18:4433-4443[Abstract/Free Full Text].
|
| 36.
|
Macleod, D.,
J. Charlton,
J. Mullins, and A. P. Bird.
1994.
Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island.
Genes Dev.
8:2282-2292[Abstract/Free Full Text].
|
| 37.
|
Magewu, A. N., and P. A. Jones.
1994.
Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer.
Mol. Cell. Biol.
14:4225-4232[Abstract/Free Full Text].
|
| 38.
|
Mao, L.,
A. Merlo,
G. Bedi,
G. I. Shapiro,
C. D. Edwards,
B. J. Rollins, and D. Sidransky.
1995.
A novel p16INK4A transcript.
Cancer Res.
55:2995-2997[Abstract/Free Full Text].
|
| 39.
|
Merlo, A.,
J. G. Herman,
L. Mao,
D. J. Lee,
E. Gabrielson,
P. C. Burger,
S. B. Baylin, and D. Sidransky.
1995.
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Nat. Med.
1:686-692[Medline].
|
| 40.
|
Michalowsky, L. A., and P. A. Jones.
1987.
Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.
Mol. Cell. Biol.
7:3076-3083[Abstract/Free Full Text].
|
| 41.
|
Mohandas, T.,
R. S. Sparkes, and L. J. Shapiro.
1981.
Reactivation of an inactive X human chromosome: evidence for X inactivation by DNA methylation.
Science
211:393-396[Abstract/Free Full Text].
|
| 42.
|
Nan, X.,
H. H. Ng,
C. A. Johnson,
C. D. Laherty,
B. M. Turner,
R. N. Eisenman, and A. Bird.
1998.
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
Nature
393:386-389[Medline].
|
| 43.
|
Okano, M.,
S. Xie, and E. Li.
1998.
Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases.
Nat. Genet.
19:219-220[Medline].
|
| 44.
|
Ottaviano, Y. L.,
J. P. Issa,
F. F. Parl,
H. S. Smith,
S. B. Baylin, and N. E. Davidson.
1994.
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.
Cancer Res.
54:2552-2555[Abstract/Free Full Text].
|
| 45.
|
Razin, A.
1984.
DNA methylation patterns: formation and biological functions, p. 127-146.
In
A. Razin, H. Cedar, and A. D. Riggs (ed.), DNA methylation: biochemistry and biological significance. Springer-Verlag Press, New York, N.Y.
|
| 46.
|
Riggs, A. D., and G. P. Pfeifer.
1992.
X-chromosome inactivation and cell memory.
Trends Genet.
8:169-174[Medline].
|
| 47.
|
Sakai, T.,
J. Toguchida,
N. Ohtani,
D. W. Yandell,
J. M. Rapaport, and T. P. Dryja.
1991.
Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene.
Am. J. Hum. Genet.
48:880-888[Medline].
|
| 48.
| Salem, C. E., I. D. C. Markl, C. M. Bender, P. A. Jones, and G. Liang. PAX6 expression and
methylation in human tumor cells. Submitted for publication.
|
| 49.
|
Szyf, M.,
V. Bozovic, and G. Tanigawa.
1991.
Growth regulation of mouse DNA methyltransferase gene expression.
J. Biol. Chem.
266:10027-10030[Abstract/Free Full Text].
|
| 50.
|
Tate, P. H., and A. P. Bird.
1993.
Effects of DNA methylation on DNA-binding proteins and gene expression.
Curr. Opin. Genet. Dev.
3:226-231[Medline].
|
| 51.
|
Taylor, S. M., and P. A. Jones.
1982.
Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA.
J. Mol. Biol.
162:679-692[Medline].
|
| 52.
|
Wutz, A.,
O. W. Smrzka,
N. Schweifer,
K. Schellander,
E. F. Wagner, and D. P. Barlow.
1997.
Imprinted expression of the Igf2r gene depends on an intronic CpG island.
Nature
389:745-749[Medline].
|
| 53.
|
Zhang, Y.,
T. Shields,
T. Crenshaw,
Y. Hao,
T. Moulton, and B. Tycko.
1993.
Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching.
Am. J. Hum. Genet.
53:113-124[Medline].
|
| 54.
|
Zion, M.,
D. Ben-Yehuda,
A. Avraham,
O. Cohen,
M. Wetzler,
D. Melloul, and Y. Ben-Neriah.
1994.
Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Proc. Natl. Acad. Sci. USA
91:10722-10726[Abstract/Free Full Text].
|
Molecular and Cellular Biology, October 1999, p. 6690-6698, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ally, M. S., Al-Ghnaniem, R., Pufulete, M.
(2009). The Relationship between Gene-Specific DNA Methylation in Leukocytes and Normal Colorectal Mucosa in Subjects with and without Colorectal Tumors. Cancer Epidemiol. Biomarkers Prev.
18: 922-928
[Abstract]
[Full Text]
-
Jin, Z., Hamilton, J. P., Yang, J., Mori, Y., Olaru, A., Sato, F., Ito, T., Kan, T., Cheng, Y., Paun, B., David, S., Beer, D. G., Agarwal, R., Abraham, J. M., Meltzer, S. J.
(2008). Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression. Cancer Epidemiol. Biomarkers Prev.
17: 111-117
[Abstract]
[Full Text]
-
Jin, Z., Olaru, A., Yang, J., Sato, F., Cheng, Y., Kan, T., Mori, Y., Mantzur, C., Paun, B., Hamilton, J. P., Ito, T., Wang, S., David, S., Agarwal, R., Beer, D. G., Abraham, J. M., Meltzer, S. J.
(2007). Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer. Clin. Cancer Res.
13: 6293-6300
[Abstract]
[Full Text]
-
Lu, R., Wang, X., Chen, Z.-F., Sun, D.-F., Tian, X.-Q., Fang, J.-Y.
(2007). Inhibition of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Decreases DNA Methylation in Colon Cancer Cells. J. Biol. Chem.
282: 12249-12259
[Abstract]
[Full Text]
-
van Rietschoten, J. G. I., Verzijlbergen, K. F., Gringhuis, S. I., Kraan, T. C. T. M. v. d. P., Bayley, J.-P., Wierenga, E. A., Jones, P. A., Kooter, J. M., Verweij, C. L.
(2006). Differentially methylated alleles in a distinct region of the human interleukin-1{alpha} promoter are associated with allele-specific expression of IL-1{alpha} in CD4+ T cells. Blood
108: 2143-2149
[Abstract]
[Full Text]
-
Ibanez de Caceres, I., Dulaimi, E., Hoffman, A. M., Al-Saleem, T., Uzzo, R. G., Cairns, P.
(2006). Identification of novel target genes by an epigenetic reactivation screen of renal cancer.. Cancer Res.
66: 5021-5028
[Abstract]
[Full Text]
-
Yang, A. S., Doshi, K. D., Choi, S.-W., Mason, J. B., Mannari, R. K., Gharybian, V., Luna, R., Rashid, A., Shen, L., Estecio, M. R.H., Kantarjian, H. M., Garcia-Manero, G., Issa, J.-P. J.
(2006). DNA Methylation Changes after 5-Aza-2'-Deoxycytidine Therapy in Patients with Leukemia.. Cancer Res.
66: 5495-5503
[Abstract]
[Full Text]
-
Lyko, F., Brown, R.
(2005). DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies. JNCI J Natl Cancer Inst
97: 1498-1506
[Abstract]
[Full Text]
-
Chan, G. C., Fish, J. E., Mawji, I. A., Leung, D. D., Rachlis, A. C., Marsden, P. A.
(2005). Epigenetic Basis for the Transcriptional Hyporesponsiveness of the Human Inducible Nitric Oxide Synthase Gene in Vascular Endothelial Cells. J. Immunol.
175: 3846-3861
[Abstract]
[Full Text]
-
Peng, B., Hodge, D. R., Thomas, S. B., Cherry, J. M., Munroe, D. J., Pompeia, C., Xiao, W., Farrar, W. L.
(2005). Epigenetic Silencing of the Human Nucleotide Excision Repair Gene, hHR23B, in Interleukin-6-responsive Multiple Myeloma KAS-6/1 Cells. J. Biol. Chem.
280: 4182-4187
[Abstract]
[Full Text]
-
Cheng, J. C., Weisenberger, D. J., Gonzales, F. A., Liang, G., Xu, G.-L., Hu, Y.-G., Marquez, V. E., Jones, P. A.
(2004). Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells. Mol. Cell. Biol.
24: 1270-1278
[Abstract]
[Full Text]
-
Weisenberger, D. J., Velicescu, M., Cheng, J. C., Gonzales, F. A., Liang, G., Jones, P. A.
(2004). Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. Mol Cancer Res
2: 62-72
[Abstract]
[Full Text]
-
Hisano, M., Ohta, H., Nishimune, Y., Nozaki, M.
(2003). Methylation of CpG dinucleotides in the open reading frame of a testicular germ cell-specific intronless gene, Tact1/Actl7b, represses its expression in somatic cells. Nucleic Acids Res
31: 4797-4804
[Abstract]
[Full Text]
-
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., Selker, E. U.
(2003). Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine. JNCI J Natl Cancer Inst
95: 399-409
[Abstract]
[Full Text]
-
Sato, F., Shibata, D., Harpaz, N., Xu, Y., Yin, J., Mori, Y., Wang, S., Olaru, A., Deacu, E., Selaru, F. M., Kimos, M. C., Hytiroglou, P., Young, J., Leggett, B., Gazdar, A. F., Toyooka, S., Abraham, J. M., Meltzer, S. J.
(2002). Aberrant Methylation of the HPP1 Gene in Ulcerative Colitis-associated Colorectal Carcinoma. Cancer Res.
62: 6820-6822
[Abstract]
[Full Text]
-
Nguyen, C. T., Weisenberger, D. J., Velicescu, M., Gonzales, F. A., Lin, J. C. Y., Liang, G., Jones, P. A.
(2002). Histone H3-Lysine 9 Methylation Is Associated with Aberrant Gene Silencing in Cancer Cells and Is Rapidly Reversed by 5-Aza-2'-deoxycytidine. Cancer Res.
62: 6456-6461
[Abstract]
[Full Text]
-
Cui, H., Fedoroff, N. V.
(2002). Inducible DNA Demethylation Mediated by the Maize Suppressor-mutator Transposon-Encoded TnpA Protein. Plant Cell
14: 2883-2899
[Abstract]
[Full Text]
-
Daskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Kohler, G., Wijermans, P., Jones, P. A., Lubbert, M.
(2002). Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood
100: 2957-2964
[Abstract]
[Full Text]
-
Carty, S. M., Greenleaf, A. L.
(2002). Hyperphosphorylated C-terminal Repeat Domain-associating Proteins in the Nuclear Proteome Link Transcription to DNA/Chromatin Modification and RNA Processing. Mol. Cell. Proteomics
1: 598-610
[Abstract]
[Full Text]
-
Bakker, J., Lin, X., Nelson, W. G.
(2002). Methyl-CpG Binding Domain Protein 2 Represses Transcription from Hypermethylated pi -Class Glutathione S-Transferase Gene Promoters in Hepatocellular Carcinoma Cells. J. Biol. Chem.
277: 22573-22580
[Abstract]
[Full Text]
-
Majumder, S., Ghoshal, K., Datta, J., Bai, S., Dong, X., Quan, N., Plass, C., Jacob, S. T.
(2002). Role of de Novo DNA Methyltransferases and Methyl CpG-binding Proteins in Gene Silencing in a Rat Hepatoma. J. Biol. Chem.
277: 16048-16058
[Abstract]
[Full Text]
-
Velicescu, M., Weisenberger, D. J., Gonzales, F. A., Tsai, Y. C., Nguyen, C. T., Jones, P. A.
(2002). Cell Division Is Required for de Novo Methylation of CpG Islands in Bladder Cancer Cells. Cancer Res.
62: 2378-2384
[Abstract]
[Full Text]
-
Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., Thykjaer, T.
(2002). Analysis of Gene Induction in Human Fibroblasts and Bladder Cancer Cells Exposed to the Methylation Inhibitor 5-Aza-2'-deoxycytidine. Cancer Res.
62: 961-966
[Abstract]
[Full Text]
-
Liang, G., Chan, M. F., Tomigahara, Y., Tsai, Y. C., Gonzales, F. A., Li, E., Laird, P. W., Jones, P. A.
(2002). Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements. Mol. Cell. Biol.
22: 480-491
[Abstract]
[Full Text]
-
Singal, R., vanWert, J. M.
(2001). De novo methylation of an embryonic globin gene during normal development is strand specific and spreads from the proximal transcribed region. Blood
98: 3441-3446
[Abstract]
[Full Text]
-
Xiong, Z., Wu, A. H., Bender, C. M., Tsao, J.-L., Blake, C., Shibata, D., Jones, P. A., Yu, M. C., Ross, R. K., Laird, P. W.
(2001). Mismatch Repair Deficiency and CpG Island Hypermethylation in Sporadic Colon Adenocarcinomas. Cancer Epidemiol. Biomarkers Prev.
10: 799-803
[Abstract]
[Full Text]
-
Pao, M. M., Tsutsumi, M., Liang, G., Uzvolgyi, E., Gonzales, F. A., Jones, P. A.
(2001). The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet
10: 903-910
[Abstract]
[Full Text]
-
Tada, Y., Wada, M., Kuroiwa, K., Kinugawa, N., Harada, T., Nagayama, J., Nakagawa, M., Naito, S., Kuwano, M.
(2000). MDR1 Gene Overexpression and Altered Degree of Methylation at the Promoter Region in Bladder Cancer during Chemotherapeutic Treatment. Clin. Cancer Res.
6: 4618-4627
[Abstract]
[Full Text]
-
Robertson, K. D., Keyomarsi, K., Gonzales, F. A., Velicescu, M., Jones, P. A.
(2000). Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cells. Nucleic Acids Res
28: 2108-2113
[Abstract]
[Full Text]
-
Salem, C., Liang, G., Tsai, Y. C., Coulter, J., Knowles, M. A., Feng, A.-C., Groshen, S., Nichols, P. W., Jones, P. A.
(2000). Progressive Increases in de Novo Methylation of CpG Islands in Bladder Cancer. Cancer Res.
60: 2473-2476
[Abstract]
[Full Text]